Laura Lane

VP Lilly Ventures , European Head at Eli Lilly & Co

Speaker

Laura Lane, PhD, is currently VP Lilly Ventures and the regional Head of Lilly Ventures for Eli Lilly & Company. Her focus is on Lilly’s venture capital strategy for Europe covering both direct investments into biotech and life science companies, and fund-of-fund relationships and investments, as well as supporting wider external innovation efforts across Lilly.

Laura is a PhD-trained scientist with diverse scientific, business, transaction and operational experience. Her experience spans: venture capital; technology transfer; the charity sector; founding and leading biotech and life science start-ups; life science consulting as well as now pharma. Prior to Lilly, Laura was part of the investment team at Advent Life Sciences; selected new investments included Highlight Therapeutics (Madrid, Spain), MiroBio (Oxford, UK) (acquired by Gilead Sciences August 2022), PIC Therapeutics (Boston, USA) and Proximie (London, UK). Prior to Advent, Laura held CEO and COO positions at several UK life science/biotech companies in Birmingham, Oxford & London.

Laura gained her masters and doctorate from the University of Cambridge and currently serves on the boards of the non-profit Collaborative Community against Coronavirus (3CCorona) CIC and the UK’s BioIndustry Association (BIA).